KLK3 and benign prostatic hyperplasia: This improvement in predictive capability translates well to the clinical setting—in essence, allowing the clinician to rule out patients with a high probability of clinically indolent disease or benign rises in PSA such as benign prostatic hyperplasia or chronic prostatitis.